Pan B-Cell Markers Are Not Redundant in Analysis of Chronic Lymphocytic Leukemia (CLL)

Cytometry Part B - Clinical Cytometry

Volumn 56, Issue 1, 2003, Pages 30-42

  Monaghan, Sara A ^a   Peterson, LoAnn C ^a   James, Cathy ^a   Marszalek, Laura ^a   Khoong, Adela ^a   Bachta, Dina J ^a   Karpus, William J ^a   Goolsby, Charles L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CD20; CD79b; Chronic lymphocytic leukemia; Flow cytometry; FMC7; Immunophenotype

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CD79B ANTIGEN; CELL MARKER; FMC7 ANTIGEN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; UNCLASSIFIED DRUG; CD79 ANTIGEN; CD79B PROTEIN, HUMAN; FMC7 PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; STAINING; CLASSIFICATION; COMPARATIVE STUDY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; PATHOLOGY; REPRODUCIBILITY;

ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD79; B-LYMPHOCYTES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOPROTEINS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 1442276358     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.10049     Document Type: Article

References (73)

1. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-1645.
2. Kurec AS, Threatte GA, Gottlieb AJ, Smith JR, Anderson J, Davey FR. Immunophenotypic subclassification of chronic lymphocytic leukiaemia (CLL). Br J Haematol 1992;81:45-51.
3. Baldini L, Cro L, Cortelezzi A, Calori R, Nobili L, Maiolo AT, Polli EE. Immunopehnotypes in "classical" B-cell chronic lymphocytic leukemia. Correlation with normal cellular counterpart and clinical findings. Cancer 1990;66:1738-1742.
4. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992;40:259-263.
5. Cossman J, Neckers LM, Hsu S, Longo D, Jaffe ES. Low-grade lymphomas. Expression of developmentally regulated B-cell antigens. Am J Pathol 1984;115:117-124.
6. Hubl W, Iturraspe J, Braylan RC. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. Cytometry 1998;34:71-74.
7. McCarrron KF, Hammel JP, His ED. Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders., Am J Clin Pathol 2000;113:805-813.
8. Brooks DA, Beckman IG, Bradley J, McNamara PJ, Thomas ME, Zola H. Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes. J Immunol 1981;126:1373-1377.
9. Catovsky D, Cherchi M, Brookss D, Bradely J, Zola H. Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7. Blood 1981;58:406-408.
10. Ferro LM, Zola H. Modulation of expression of the antigen identified by FMC7 upon human B-lymphocyte activation: evidence for differences between activation in vivo and in vitro. Immunology 1990;69:373-378.
11. Huh YO, Pugh WC, Kantarjian HM, Stass SA, Cork A, Trujillo JM, Keating MJ. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol 1994;101:283-289.
12. Serke S, Schwaner I, Yordanova M, Szczepek A, Huhn D. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry 2001;46:98-104.
13. Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D. Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia 1996;10:1966-1970.
14. Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, Seon BK, Catovsky D. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378-382.
15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 1989;42:567-584.
16. Goolsby CL, James C. Basic flow cytometry instrumentation. In: Patterson BK, editor. Techniques in quantification and localization of gene expression. Boston: Birkhauser; 2000. p 3-22.
17. D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000;64:275-281.
18. Gong JZ, Lagoo AS, Peters D, Horvatinovich J, Benz P, Buckley PJ. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol 2001;116:893-897.
19. Decaudin D, Brousse N, Brice P, Haioun C, Bourhis JH, Morel P, Van Hoof A, Souleau B, Quesnel B, Gisselbrecht C. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Bone Marrow Transplant 2000;25:251-256.
20. Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002;29:56-69.
21. Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F, Callet-Bauchu E, Felman P, Berger F, Salles G, Coiffier B. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998;12:1281-1287.
22. Vose JM, Bierman PJ, Weisenburger DD, Lynch JC, Bociek Y, Chan WC, Greiner TC, Armitage JO. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000;6:640-645.
23. Belaud-Rotureau MA, Parrens M, Dubus P, Garroste JC, De Mascarel A, Merlio JP. A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol 2002;15:517-525.
24. Katz RL, Caraway NP, Gu J, Jiang F, Pasco-Miller LA, Glassman AB, Luthra R, Hayes KJ, Romaguera JE, Cabanillas FF, Medeiros LJ. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma. Am J Clin Pathol 2000;114:248-257.
25. Kurtin PJ, Hobday KS, Ziesmer S, Caron BL. Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am J Clin Pathol 1999;112:319-329.
26. Remstein ED, Kurtin PJ, Buno I, Bailey RJ, Proffitt J, Wyatt WA, Hanson CA, Dewald GW. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol 2000;110:856-862.
27. Ballesteros E, Osborne BM, Matsushima AY. CD5+ low-grade marginal zone B-cell lymphomas with localized presentation. Am J Surg Pathol 1998;22:201-207.
28. Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL. CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 1996;105:31-37.
29. Heuring AH, Franke FE, Hutz WW. Conjunctival CD5+ MALT lymphoma. Br J Ophthalmol 2001;85:498-499.
30. Hall PA, D'Ardenne AJ, Richards MA, Stansfeld AG. Lymphoplasmacytoid lymphoma: an immunohistological study. J Pathol 1987;153:213-223.
31. Owen RG, Barrans SL, Richards SJ, O'Connor SJ, Child JA, Parapia LA, Morgan GJ, Jack AS. Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001;116:420-428.
32. Papamichael D, Norton AJ, Foran JM, Mulatero C, Mathews J, Amess JA, Bradburn M, Lister TA, Rohatiner AZ. Immunocytoma: a retrospective analysis from St Bartholomew's Hospital - 1972 to 1996. J Clin Oncol 1999;17:2847-2853.
33. Schwonzen M, Pohl C, Steinmetz T, Seckler W, Vetten B, Thiele J, Wickramanayake D, Diehl V. Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification. Br J Haematol 1993;83:232-239.
34. Harada S, Suzuki R, Uehira K, Yatabe Y, Kagami Y, Ogura M, Suzuki H, Oyama A, Kodera Y, Ueda R, Morishima Y, Nakamura S, Seto M. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia 1999;13:1441-1447.
35. Khalidi HS, Brynes RK, Browne P, Koo CH, Battifora H, Medeiros LJ. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Mod Pathol 1998;11:983-988.
36. Kroft SH, Howard MS, Picker LJ, Ansari MQ, Aquino DB, McKenna RW. De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma. Am J Clin Pathol 2000;114:523-533.
37. Kume M, Suzuki R, Yatabe Y, Kagami Y, Miura I, Miura AB, Morishima Y, Nakamura S, Seto M. Somatic hypermutations in the VH segment of immunoglobulin genes of CD5-positive diffuse large B-cell lymphomas. Jpn J Cancer Res 1997;88:1087-1093.
38. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 1995;147:207-216.
39. Nakamura N, Hashimoto Y, Kuze T, Tasaki K, Sasaki Y, Sato M, Abe M. Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma. Lab Invest 1999;79:925-933.
40. Taniguchi M, Oka K, Hiasa A, Yamaguchi M, Ohno T, Kita K, Shiku H. De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood 1998;91:1145-1151.
41. Yamaguchi M, Ohno T, Oka K, Taniguchi M, Ito M, Kita K, Shiku H. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol 1999;105:1133-1139.
42. Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, Suzumiya J, Murase T, Miura I, Akasaka T, Tamaru J, Suzuki R, Kagami Y, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002;99:815-821.
43. Hercher C, Robain M, Davi F, Garand R, Flandrin G, Valensi F, Vandeputte H, Albert A, Maynadie M, Troussard X, Simon GH, Lespinasse J, Portefaix G, Merle-Beral H. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 2001;42:981-987.
44. Schlette E, Bueso-Ramos C, Giles F, Glassman A, Hayes K, Medeiros LJ. Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 2001;115:571-581.
45. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
46. Gahrton G, Robert KH, Friberg K, Zech L, Bird AG. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation. Blood 1980;56:640-647.
47. Juliusson G, Gahrton G. Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications. Cancer Genet Cytogenet 1990;45:143-160.
48. Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. Semin Oncol 1998;25:19-26.
49. Morita M, Minowada J, Sandberg AA. Chromosomes and causation of human cancer and leukemia. Chromosome patterns in stimulated lymphocytes of chronic lymphocytic leukemia. Cancer Genet Cytogenet 1981;3:293-306.
50. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999;77:266-281.
51. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
52. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
53. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
54. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997;89:4153-4160.
55. Tworek JA, Singleton TP, Schnitzer B, Hsi ED, Ross CW. Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Am J Clin Pathol 1998;110:582-589.
56. Brown MC, Hoffman RA, Kirchanski SJ. Controls for flow cytometers in hematology and cellular immunology. Ann NY Acad Sci 1986;468:93-103.
57. Gratama JW, D'Hautcourt JL, Mandy F, Rothe G, Barnett D, Janossy G, Papa S, Schmitz G, Lenkei R. Flow cytometric quantitation of immunofluorescence intensity: problems and perspectives. European Working Group on Clinical Cell Analysis. Cytometry 1998;33:166-178.
58. Henderson LO, Marti GE, Gaigalas A, Hannon WH, Vogt RF, Jr. Terminology and nomenclature for standardization in quantitative fluorescence cytometry. Cytometry 1998;33:97-105.
59. Schwartz A, Marti GE, Poon R, Gratama JW, Fernandez-Repollet E. Standardizing flow cytometry: a classification system of fluorescence standards used for flow cytometry. Cytometry 1998;33:106-114.
60. Stirnan O, Burshteyn A. Cell surface receptor-antibody association constants and enumeration of receptor sites for monoclonal antibodies. Cytometry 2000;40:316-326.
61. Vogt RF Jr Whitfield WE, Henderson LO, Hannon WH. Fluorescence intensity calibration for immunophenotyping by flow cytometry. Methods 2000;21:289-296.
62. Zenger VE, Vogt R, Mandy F, Schwartz A, Marti GE. Quantitative flow cytometry: inter-laboratory variation. Cytometry 1998;33:138-145.
63. Borowitz MJ, Bray R, Gascoyne R, Melnick S, Parker JW, Picker L, Stetler-Stevenson M. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry 1997;30:236-244.
64. Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001;116:437-443.
65. Criel A, Verhoef G, Vlietinck R, Mecucci C, Billiet J, Michaux L, Meeus P, Louwagie A, Van Orshoven A, Van Hoof A, Boogaerts M, Van den Berghe H, De Wolf-Peeters C. Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases. Br J Haematol 1997;97:383-391.
66. Finn WG, Thangavelu M, Yelavarthi KK, Goolsby CL, Tallman MS, Traynor A, Peterson LC. Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. Am J Clin Pathol 1996;105:458-467.
67. Kroft SH, Finn WG, Kay NE, Peterson LC. Isolated 13q14 abnormalities and normal karyotypes are associated with typical lymphocyte morphology in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 1997;107:275-282.
68. Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996;92:382-388.
69. Que TH, Marco JG, Ellis J, Matutes E, Babapulle VB, Boyle S, Catovsky D. Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology. Blood 1993;82:571-575.
70. Su'ut L, O'Connor SJ, Richards SJ, Jones RA, Roberts BE, Davies FE, Fegan CD, Jack AS, Morgan GJ. Trisomy 12 is seen within a specific subtype of B-cell chronic lymphoproliferative disease affecting the peripheral blood/bone marrow and co-segregates with elevated expression of CD11a. Br J Haematol 1998;101:165-170.
71. Tabernero MD, San Miguel JF, Garcia JL, Garcia-Isidoro M, Wiegant J, Ciudad J, Gonzalez M, Rios A, Raap A, Orfao A. Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. Cytometry 1995;22:217-222.
72. Cabezudo E, Carrara P, Morilla R, Matutes E. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica 1999;84:413-418.
73. Kroft SH, Dawson DB, McKenna RW. Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol 2001;115:385-395.